Furthermore, the ΔNp63α/ribosome S6 protein kinase 4 (RSK4)/glycogen synthase kinase 3β (GSK-3β) axis contributes to CSC properties and radio-resistance in ESCC, suggesting that RSK4 is a promising therapeutic target386. The gene discussed is RPS6KA6; the disease is esophageal squamous cell carcinoma.